INTRODUCTION
============

Boerhaave syndrome (BS), a rare condition associated with high mortality \[[@b1-ce-2017-043]\], is defined as a spontaneous esophageal perforation of a normal esophagus unrelated to foreign bodies, previous instrumentation, surgery, or trauma \[[@b2-ce-2017-043]\]. In cases of an early diagnosis and clinical presentation of sepsis, surgical treatment is favored. If it is diagnosed within the first 48 hours and there are no sepsis signs and minimal contamination, the endoscopic approach is preferred \[[@b3-ce-2017-043]\]. Conservative management has rarely been reported in case series, but it could be proposed to patients with delayed diagnosis, no sepsis, and good tolerance of pleural contamination. Those in whom this approach fails are usually reconsidered for surgical management \[[@b4-ce-2017-043],[@b5-ce-2017-043]\]. However, the development of endoscopic therapies (ET) may change the management of BS due to a mini-invasive approach and the use of different methods to close the defects without the risks of open surgery. Indeed, there are several case reports and publications in the literature regarding the endoscopic treatment of BS. This is our experience with the endoscopic management of BS.

CASE REPORT
===========

Patients and methods
--------------------

We included all adult patients (\>18 years) referred to our gastrointestinal and Endoscopy Unit who were diagnosed with a BS perforation between June 2004 and August 2015. Those patients who had another final diagnosis were excluded. All patients provided informed consent. This was a retrospective, observational, mono-centric, single-arm, consecutive case-series study that was not registered as a clinical trial and did not require institutional review board approval.

Included data: patient demographics, comorbidities, lesion characteristics, intended treatment (conservative, endoscopic, or surgical), need for additional treatments (if first attempt/approach fails), length of treatment, success rates, survival rates, and long-term follow-up.

The modalities used for patients who underwent ET included 12/6 t over-the-scope-clips (OTSC); esophageal self-expandable metallic stents (SEMS); through-the-scope clips; and local therapies consisting of through-the-scope lavage of mediastinal and/or pleural cavities, local antibiotics, and a novel therapy, internal drains (materials listed in [Table 1](#t1-ce-2017-043){ref-type="table"}). Endoscopies were performed by the interventional endoscopic team. A therapeutic videogastroscope with a large 3.8-mm working channel (PENTAX Medical, Tokyo, Japan) was used. The therapeutic approach was determined using the endoscopist criteria in a case-by-case manner.

All patients were transferred to the intensive care unit with antibiotics, proton pump inhibitors, and enteral or parenteral nutrition support. The follow-up was performed by the Thoracic Surgery or Gastroenterology Departments.

Results
-------

A total of 14 patients with BS were included ([Table 2](#t2-ce-2017-043){ref-type="table"}). All patients underwent upper-gastrointestinal endoscopy to confirm the diagnosis or for ET.

Only one patient received neither ET nor surgery and was managed conservatively (antibiotics, fasting, and fluid compensation) with a good outcome. Another patient was treated with computed tomography (CT)---guided percutaneous drainage of a collection seen on a CT scan as the first approach, secondarily completed by ET (metallic stenting). Surgery was the primary treatment modality in 10 patients, while ET was the primary intervention in two patients. ET was offered as primary treatment from 2010 onward; starting in 2015, patients also benefited from local ET. Thirteen of 14 patients required an internal, external, radiologically guided, or surgical drain.

All of the patients underwent an endoscopic procedure. Seven were exclusive diagnostic procedures; of them, four were performed at the initial management in the operating room and followed by surgery because of size or lesion localization. The other seven had ET. Only two underwent ET as first-line therapy: one had a successful treatment after Ovesco clipping with stenting followed by local ET and internal drains; the other was too unstable for surgery so an endoscopic approach was used, but this patient died of sepsis assertion and multi-organ failure within the first 24 hours.

Ten patients underwent a primary surgical therapy, four underwent external drain (ED) (pleural and/or mediastinal) placement, three underwent esophageal repair of the perforation with esophageal suturing and ED placement, two underwent esophageal repair of the perforation with a suture in addition to Nissen fundoplication (not the most popular approach) with ED placement, while only one underwent esophagectomy with cardias resection for treatment of a very large perforation. Among them, three had primary efficacy (ED and primary repair with esophageal suturing), while one died after surgery (esophagectomy). The other six patients from the surgical treated group required second line treatment. Four of six needed a second surgical procedure; of these four, three had an esophageal repair of the perforation with suture. Of these three patients, two healed and the other required ET. The remaining patient required (after Nissen fundoplication) an esophageal repair with suture reinforcement of the fundoplication, although he ultimately required supplemental ET.

Five patients ultimately required ET as a "salvage" treatment. Two patients benefited from SEMS after a primary surgical treatment, while another benefited from SEMS after CT-guided percutaneous drain placement. Two patients required last-line salvage therapy after the failure of more than one surgical intervention: one who underwent previous ED placement + oversewing/primary suture benefited from an Ovesco clip + local ET + SEMS; the other benefited from SEMS after two fundoplications. The clinical progress of these patients is shown in [Fig. 1](#f1-ce-2017-043){ref-type="fig"} and [Table 1](#t1-ce-2017-043){ref-type="table"}.

In summary, the overall clinical success of the exclusive surgical management of BS was achieved in 50% of the patients ([Table 3](#t3-ce-2017-043){ref-type="table"}). Treatment failed in the other half of the patients; one died, as mentioned above, so 40% required ET. The overall clinical success of ET, meaning total wall healing, was 85%. One patient died within the 24 hours after the first intervention ([Table 3](#t3-ce-2017-043){ref-type="table"}).

Only one patient required a single ET procedure. All patients required SEMS: a total of 13 stents were deployed, and the migration rate was 31%. Three patients underwent OTSC placement associated with SEMS ([Table 1](#t1-ce-2017-043){ref-type="table"}).

Finally, after ET, none of the patients required an additional surgery. All of the patients were discharged with oral intake and without ED except for the patient with the internal naso-collection drain that was managed as outpatient ambulatory care until complete resolution of the para-esophageal/mediastinal collection was achieved.

Four patients had complications. One patient experienced a cysto-bronchial fistula during ET that was successfully treated with the endoscopic placement of cystic internal drains (double pig tail plastic stents). Two patients had esophageal stenosis post-stenting that was successfully treated with endoscopic dilatation. One surgically treated patient presented with pneumonia in the follow-up period and underwent antibiotic treatment and surgical repair of the abdominal wall defect ([Table 1](#t1-ce-2017-043){ref-type="table"}).

DISCUSSION
==========

The current management of BS includes conservative, endoscopic, and surgical treatments. The survival rates for each treatment are 75%, 100%, and 81%, respectively. The estimated global mortality rate of patients with BS is 20%--40% \[[@b3-ce-2017-043]\].

Endoscopy is a proven effective tool in the diagnosis of BS, particularly in cases in which the diagnosis is suspected but findings on CT or a swallow study are inconclusive, because endoscopy enables specific lesion characterization. Our endoscopic descriptions were consistent with those in the literature, as lesion size 2.2 cm long and localized in the left lateral position of the lower esophagus in 90% of cases ([Table 2](#t2-ce-2017-043){ref-type="table"}) \[[@b3-ce-2017-043]\].

Regarding endoscopic treatment, different therapeutic mechanisms can be proposed: derivation with self-expandable stents; closing with OTSC or other clipping devices; and local therapies consisting of through-the-scope lavage, local antibiotics, and naso-collection or double pig-tail internal drains. SEMS have been widely evaluated for use in cases of esophageal fistulas/leakage \[[@b6-ce-2017-043]\] including patients with BS. In fact, the use of esophageal stents in association with chest tube drainage helped avoid surgery in 60% of patients in the first published series \[[@b7-ce-2017-043]\] and displayed 100% clinical success in a recent study \[[@b8-ce-2017-043]\]. Adverse events, consisting of an overall migration rate of 31%, seems to be lower in our series 14% migration risk with fully covered double-type metallic stents (1/7), as previously described by our team \[[@b6-ce-2017-043]\]. Nevertheless, stent migration did not modify the clinical outcomes of our series because total wall healing was achieved in the majority of cases.

Regarding direct closure, seven cases requiring use of OTSC to treat BS were reported in the literature \[[@b9-ce-2017-043],[@b10-ce-2017-043]\]. The majority of cases required drain placement for the treatment of a contaminated cavity, and all were clinical successes. Five other cases were successfully treated with combination therapy consisting of OTSC or through-the-scope clips with a complementary metallic stent \[[@b10-ce-2017-043],[@b11-ce-2017-043]\]. Another study \[[@b10-ce-2017-043]\] described the use of the Apollo Overstitch device alone, or with OTSC or through-the-scope clips in combination with SEMS in lesions yielded incomplete closure, in smaller lesion presentation than those in our series (median size of 1 cm). Accordingly, OTSC might be more useful for perforations located in the esophagogastric junction that are \<20 mm. Nevertheless, our patients had 20-, 20-, and 40-mm lesions and required additional ET, stenting, local therapies, and additional internal drains, probably due to large perforations or unfavorable localization.

In our series, one patient underwent combined therapy consisting of OTSC and SEMS for dehiscent closure. Thereafter, he benefited from ET (through-the-scope lavage) and was additionally treated with a novel technique: an internal naso-collection drain into a mediastinal collection including suction rinsing lavage and local antibiotics. After 8 months and eight endoscopic procedures, he completely recovered. Consequently, for pure esophageal perforations, the combination of OTSC with fully covered SEMS seems to have increased efficacy.

Although this was a heterogeneous population due to the retrospective nature of the study, we can conclude that the endoscopic treatment of BS is effective given the relatively low mortality rate in our series. This study displays our experience with this rare but very severe pathology, underlying the place of endoscopy as a diagnostic tool; treatment option when previous surgery attempts fail; primary treatment choice in selected patients with no septic signs or minimal cavity contamination in combination with drains; or treatment for patients who are not surgical candidates. The devices and techniques described could be combined to better resolve this problem. Ideally, a prospective study could help support and strengthen the recommendations displayed on this series and in the literature as well as define the indications, timing, anatomical characteristics, and sizes for which each treatment should be used.
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![Global management strategies, progression, and outcomes. CT, computed tomography; ES, oversewing/primary suture.](ce-2017-043f1){#f1-ce-2017-043}

###### 

Step-by-Step Details of the Surgical and Endoscopic Procedures including Technical Characteristics and Complications

  Case No.   Year   Conduct                                                                                                                                                                                                                                          Complication
  ---------- ------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------
  1          2004   Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + ES + Nissen fundoplication                                                                                                                                                                 Suture dehiscence
                    AR-FCMS^[b)](#tfn2-ce-2017-043){ref-type="table-fn"}^ 90×22 mm                                                                                                                                                                                   Stent migration
                    AR-FCMS^[b)](#tfn2-ce-2017-043){ref-type="table-fn"}^ 160×22 mm                                                                                                                                                                                  
                    AR-FCMS^[b)](#tfn2-ce-2017-043){ref-type="table-fn"}^ 90×22 mm                                                                                                                                                                                   
                    Treatment success, discharge                                                                                                                                                                                                                     Post-stent stenosis
  2          2008   Diagnostic                                                                                                                                                                                                                                       
                    Drains^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + ES                                                                                                                                                                                        
                    Treatment success, discharge                                                                                                                                                                                                                     
  3          2010   Diagnostic                                                                                                                                                                                                                                       
                    Conservative treatment                                                                                                                                                                                                                           
                    Treatment success, discharge                                                                                                                                                                                                                     
  4          2010   Drains^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^                                                                                                                                                                                             
                    Diagnostic                                                                                                                                                                                                                                       
                    ES                                                                                                                                                                                                                                               
                    Treatment success, discharge                                                                                                                                                                                                                     
  5          2011   Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^                                                                                                                                                                                              
                    CMS^[c)](#tfn3-ce-2017-043){ref-type="table-fn"}^ 120×18 mm                                                                                                                                                                                      Stent migration
                    FCMS^[d)](#tfn4-ce-2017-043){ref-type="table-fn"}^ 120×24 mm                                                                                                                                                                                     Stent migration
                    FCMS^[e)](#tfn5-ce-2017-043){ref-type="table-fn"}^ 120×20 mm                                                                                                                                                                                     
                    Treatment success, discharge                                                                                                                                                                                                                     
  6          2011   Diagnostic                                                                                                                                                                                                                                       
                    Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + ES                                                                                                                                                                                         
                    Treatment success, discharge                                                                                                                                                                                                                     
  7          2011   Diagnostic                                                                                                                                                                                                                                       
                    Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + ES                                                                                                                                                                                         
                    Treatment success, discharge                                                                                                                                                                                                                     
  8          2012   Diagnostic                                                                                                                                                                                                                                       Died first 24 hr post treatment
                    Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + Lewy Santy                                                                                                                                                                                 
  9          2013   Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^                                                                                                                                                                                              
                    Diagnostic                                                                                                                                                                                                                                       
                    Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + ES                                                                                                                                                                                         
                    Treatment success, discharge                                                                                                                                                                                                                     Pneumonia, eventration
  10         2013   Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + LM, LP + OTSC^[f)](#tfn6-ce-2017-043){ref-type="table-fn"}^ + FCMS^[g)](#tfn7-ce-2017-043){ref-type="table-fn"}^ 120×20 mm fixed w/2 clips^[h)](#tfn8-ce-2017-043){ref-type="table-fn"}^   Died first 24 hr post treatment
  11         2014   Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + Nissen fundoplication                                                                                                                                                                      Suture leakage
                    ES + Fundoplication reinforcement                                                                                                                                                                                                                
                    FCMS^[e)](#tfn5-ce-2017-043){ref-type="table-fn"}^ 150×20 mm                                                                                                                                                                                     
                    Treatment success, discharge                                                                                                                                                                                                                     
  12         2014   Drain^[i)](#tfn9-ce-2017-043){ref-type="table-fn"}^ + FCMS^[e)](#tfn5-ce-2017-043){ref-type="table-fn"}^ 150×20 mm fixed w/2 clips^[h)](#tfn8-ce-2017-043){ref-type="table-fn"}^                                                                 Stent migration
                    FCMS re-fixed w/3 clips^[h)](#tfn8-ce-2017-043){ref-type="table-fn"}^                                                                                                                                                                            
                    Treatment success, discharge                                                                                                                                                                                                                     Post-stent stenosis
  13         2015   LP + local ATB + OTSC^[f)](#tfn6-ce-2017-043){ref-type="table-fn"}^ + esophageal tube w/continue aspiration                                                                                                                                      Suture dehiscense
                    LP + local ATB + FCMS^[e)](#tfn5-ce-2017-043){ref-type="table-fn"}^ 150×20 mm                                                                                                                                                                    
                    LP + naso-cystic internal drain                                                                                                                                                                                                                  
                    LP + local ATB + FCMS^[e)](#tfn5-ce-2017-043){ref-type="table-fn"}^ 150×20 mm                                                                                                                                                                    
                    LP + naso-cystic internal drain                                                                                                                                                                                                                  
                    Drain in place + double pig tail plastic stent^[h)](#tfn8-ce-2017-043){ref-type="table-fn"}^ 7 Fr 10 cm                                                                                                                                          Cysto-bronchial fistula
                    Drain in place + FCMS^[e)](#tfn5-ce-2017-043){ref-type="table-fn"}^ 150×20 mm                                                                                                                                                                    
                    Metallic stent removal + naso-cystic drain in place + oral refeeding, discharge                                                                                                                                                                  
  14         2015   Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^                                                                                                                                                                                              
                    ES                                                                                                                                                                                                                                               Suture leakage
                    Drain^[a)](#tfn1-ce-2017-043){ref-type="table-fn"}^ + LP + local ATB +OTSC^[f)](#tfn6-ce-2017-043){ref-type="table-fn"}^                                                                                                                         Insufficient closure
                    LP + FCMS^[e)](#tfn5-ce-2017-043){ref-type="table-fn"}^ 120×AR-FCMS 20 mm fixed x/2 clips^[h)](#tfn8-ce-2017-043){ref-type="table-fn"}^                                                                                                          
                    Discharge                                                                                                                                                                                                                                        
                    Endoscopic control: in place and permeable stent                                                                                                                                                                                                 
                    Metallic stent removal + control: fistula closure                                                                                                                                                                                                

Nasogastric tube for esophageal aspiration.

ES, oversewing/primary suture; AR-FCMS, anti-reflux fully covered metallic stent; CMS, covered metallic stent; endoscopic mediastinal cavity lavage; LP, endoscopic pleural cavity lavage; OTSC, over-the-scope-clips; ATB, amikacin (local), augmentin (amoxicillin+clavulanic acid, IV).

Previous surgical external drain.

Hanarostent; Life Partners Europe, Bagnolet, France.

Ultraflex NG covered; Boston Scientific, Marlborough, MA, USA.

Niti S enteral colonic; TaeWoong Medical, Seoul, Korea.

Niti S double; TaeWoong Medical, Seoul, Korea.

Ovesco Endoscopy AG, Tübingen, Germany.

Niti S; TaeWoong Medical, Seoul, Korea.

Cook, Bloomington, IN, USA.

Previous computed tomography-guided percutaneous drain.

###### 

Population, Clinical Onset, Diagnosis, and Endoscopic Findings

  --------------------- --------------------------------------------------------------------------------------------------
  Gender                4 F/ 10 M
  Mean age              65, 21 yr (range, 41--82 yr)
  Procedence            57.14% transferred from another hospital
  Admission             92.85% at the urgency unit
  Primary symptom       9/14 vomiting and chest or abdominal pain
  Diagnosis method      11/14 patients (78%) was achieved with CT scan
  Debut symptoms to     7/14 (50%) \<24 hr
  Endoscopy             3/14 between 24 hr, 4 days
                        4/14 longer time to endoscopy: 6, 16, 40, 60 days (due to prior surgery or a delayed derivation)
  Endoscopic findings   11/14 lower esophagus
                        3/14 esophago-gastric junction
  Lesion localisation   Lower esophagus: 6/11 left side, 4/11 anterior, 1/11 posterior
                        33% localized at erythematous or ulcerated mucosa
  Median lesion size    3 cm (range, 0.3--5 cm)
  CO~2~ Insuflator      From 2013 all procedures were made with this device
  --------------------- --------------------------------------------------------------------------------------------------

CT, computed tomography; CO~2~, carbon dioxide.

###### 

Treatment Outcomes: Clinical Success Rates, Treatment Time, Number Procedures, Follow up, Number of Complications

                                                   Surgical therapy   Endoscopic therapy
  ------------------------------------------------ ------------------ --------------------
  Clinical success (%)                             50                 85
  Median time of treatment: mo (range)             1 (1--2)           3 (1--8)
  Median number of procedures to achieve success   1, 4 (1--2)        3 (1--8)
  Median time of follow up: mo (range)             6 (2--12)          6 (2--12)
  Number of deaths                                 1                  1
  Complications (numbers)                          1                  3
